Maud Beillat
Overview
Explore the profile of Maud Beillat including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
263
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Beillat M, Durand-Zaleski I, Pirenne F, Benard S, Chillotti L, Galacteros F
Front Public Health
. 2023 Oct;
11:1215605.
PMID: 37808997
Sickle cell disease (SCD) is a genetic disorder of the hemoglobin resulting in chronic anemia, hemolysis, and vaso-occlusions. Its treatment mostly relies on hydroxycarbamide, transfusions, and stem cell transplantation. This...
2.
Galacteros F, Ethgen O, Beillat M
PLoS One
. 2023 Sep;
18(9):e0291211.
PMID: 37703228
Sickle cell disease (SCD) is an inherited blood disorder in which sickle hemoglobin (HbS) polymerizes, leading to red blood cell sickling and chronic hemolytic anemia, vaso-occlusive crises, and end-organ damage...
3.
Nguyen-Thi H, Nguyen N, Le N, Beillat M, Ethgen O
Front Public Health
. 2020 Nov;
8:562023.
PMID: 33194963
ADVANCE was a large, multinational clinical study conducted over 5 years in type 2 diabetes mellitus (T2DM). In all, 11,140 patients were randomly assigned to receive gliclazide-based intensive glucose control...
4.
Alzaid A, Ladron de Guevara P, Beillat M, Lehner Martin V, Atanasov P
Expert Rev Pharmacoecon Outcomes Res
. 2020 Jul;
21(4):785-798.
PMID: 32686530
To estimate the clinical and economic burden of type 2 diabetes (T2D) in established (EST) and emerging markets (EMG). Three systematic literature reviews were conducted in MEDLINE and Embase to...
5.
Potkin S, Loze J, Forray C, Baker R, Sapin C, Peters-Strickland T, et al.
PLoS One
. 2017 Aug;
12(8):e0183475.
PMID: 28837593
Schizophrenia is a chronic disease with negative impact on patients' employment status and quality of life. This post-hoc analysis uses data from the QUALIFY study to elucidate the relationship between...
6.
Potkin S, Loze J, Forray C, Baker R, Sapin C, Peters-Strickland T, et al.
Int Clin Psychopharmacol
. 2017 Mar;
32(3):147-154.
PMID: 28252452
Sexual dysfunction, a common side effect of antipsychotic medications, may be partly caused by dopamine antagonism and elevation of prolactin. In QUALIFY, a randomized study, aripiprazole once-monthly 400 mg (AOM...
7.
Potkin S, Loze J, Forray C, Baker R, Sapin C, Peters-Strickland T, et al.
Int J Neuropsychopharmacol
. 2016 Dec;
20(1):40-49.
PMID: 27927736
Background: QUALIFY was a 28-week, randomized, open-label, head-to-head trial that assessed improvements across multiple measures in stable patients with schizophrenia with aripiprazole once-monthly 400 mg vs paliperidone palmitate. Methods: Secondary...
8.
Sapin C, Hartry A, Kamat S, Beillat M, Baker R, Eramo A
Drugs Context
. 2016 Oct;
5:212301.
PMID: 27708677
Schizophrenia presents a substantial clinical and economic burden to the health-care system. In QUAlity of LIfe with AbiliFY Maintena (QUALIFY), a randomized head-to-head study of aripiprazole once-monthly 400 mg (AOM...
9.
Majer I, Gaughran F, Sapin C, Beillat M, Treur M
J Mark Access Health Policy
. 2016 Apr;
3.
PMID: 27123183
Background: Treatment with long-acting injectable (LAI) antipsychotic medication is an important element of relapse prevention in schizophrenia. Recently, the intramuscular once-monthly formulation of aripiprazole received marketing approval in Europe and...
10.
Tempest M, Sapin C, Beillat M, Robinson P, Treur M
J Ment Health Policy Econ
. 2016 Jan;
18(4):185-200.
PMID: 26729007
Background: Schizophrenia is a severe and debilitating psychiatric disorder. Pharmacological interventions aim to ameliorate symptoms and reduce the risk of relapse and costly hospitalisation. Despite the established efficacy of antipsychotic...